Evidence map›Paper›PMID 32965595›Full record

ArticleMolecular and cellular biochemistry2021

Gallic acid ameliorates COPD-associated exacerbation in mice.

Esha Singla, Gayatri Puri, Vivek Dharwal, Amarjit S Naura

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. [Therapeutic effects of natural products on animal models of chronic obstructive pulmonary disease].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  7. Toxicological assessment ofFrontiers in toxicology · 2025
    Article
  8. Carboxylic Acids as Activators of NRF2: Antioxidant and Anti-inflammatory Effects.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Polyphenols, flavonoids and inflammasomes: the role of cigarette smoke in COPD.European respiratory review : an official journal of the European Respiratory Society · 2022
    Review
  20. Metformin alleviates chronic obstructive pulmonary disease and cigarette smoke extract-induced glucocorticoid resistance by activating the nuclear factor E2-related factor 2/heme oxygenase-1 signaling pathway.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Esha SinglaDepartment of Biochemistry, Panjab University, Chandigarh, 160014, India.
Gayatri PuriDepartment of Biochemistry, Panjab University, Chandigarh, 160014, India.
Vivek DharwalDepartment of Biochemistry, Panjab University, Chandigarh, 160014, India.
Amarjit S NauraDepartment of Biochemistry, Panjab University, Chandigarh, 160014, India. anaura@pu.ac.in.ORCID http://orcid.org/0000-0002-2797-0432
Panjab University · IN

Funding

Department of Biotechnology , Ministry of Science and Technology BT/PR17968/MED/122/33/2016Indian Council of Medical Research SRFUniversity Grants Commission SAP
6 · The paper itself

Abstract

COPD is an inflammatory lung disease, which is often exacerbated with microbial infections resulting in worsening of respiratory symptoms. Gallic acid (GA), a naturally occurring phenolic compound is known to possess anti-oxidant/anti-inflammatory activity. We have recently reported that GA protects against the elastase (ET) induced lung inflammation and emphysema and the present work was designed to investigate the beneficial effects of Gallic acid against ET + Lipopolysachharide (LPS) induced COPD exacerbation like condition in mice model. Our data showed that i.t. administration of LPS at 21 days after ET instillation resulted in significant infiltration of inflammatory cells particularly neutrophils (p < 0.0001) into the lungs along with elevated levels of pro-inflammatory cytokines like TNF-α, IL-1β and IL-6 (p < 0.0001). Interestingly, daily administration of GA (200 mg/Kg b. wt.) starting 7 days before ET instillation, significantly blunted the ET + LPS induced inflammation as indicated by reduced number of inflammatory cells particularly neutrophils (p < 0.0001) in BALF along with suppression of myeloperoxidase activity (p = 0.0009) and production of pro-inflammatory cytokines (p < 0.0001). Further, GA also restored the redox imbalance in the lungs towards normal. Additionally, phosphorylation of p65-NF-κB was found to be reduced (p = 0.015), which was associated with downregulation in the gene expression of IL-1β (p = 0.022) and TNF-α (p = 0.04). Conversely, GA treatment resulted in increased protein levels of Nrf2 (p = 0.021) with concomitant increase in transcription of its downstream target genes HO-1 (p = 0.033) and Prdx-1 (p = 0.006). Overall, our data show that GA effectively modulates COPD exacerbation manifestations in mice potentially by restoring redox imbalance in lungs.

Indexed as

AnimalsAnti-Inflammatory AgentsAntioxidantsCytokinesEnzyme-Linked Immunosorbent AssayGallic AcidInflammationLipopolysaccharidesMaleMiceMice, Inbred BALB CNeutrophilsOxidation-ReductionOxidative StressPeroxidasePolyphenolsAnti-Inflammatory AgentsAntioxidantsCytokinesGallic AcidLipopolysaccharidesPeroxidasePolyphenolsCOPD exacerbationGallic acidLPSNF-κBNrf2

Identifiers

PMID32965595
OpenAlexW3088340379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.